Authors: M. M. Dolzhenko, MD, Professor, Head of the Department of Cardiology, Yu. P. L.Shupika, Kyiv
Celecoxib is a powerful NSAID that is generally well tolerated by patients. According to the data of clinical trials, increased hepato- and nephrotoxicity of this medicine as compared to other selective and non-selective NSAIDs was not established.
As reporting by recent studies, celecoxib is a possible candidate for use in oncology to minimize excessive tumor growth and in psychiatry to reduce depression and improve cognitive function, but further large studies are needed.
Recently, the Ukrainian pharmaceutical market was replenished with a new high-quality and affordable celecoxib called LEKOXA produced by the World Medicine company.